AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca is conducting a Phase II study titled A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria. The study aims to evaluate the efficacy, safety, and tolerability of a combination treatment of zibotentan and dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease (CKD) and high proteinuria. This research is significant as it could lead to new treatment options for CKD patients, particularly in the Eurasian Economic Union.
Intervention/Treatment: The study tests two interventions: a fixed-dose combination of zibotentan and dapagliflozin, and dapagliflozin alone. These are oral medications intended to manage CKD and high proteinuria, potentially improving patient outcomes.
Study Design: This is a multicentre, randomized, double-blind, active-controlled study with a parallel-group design. Participants are randomly assigned to receive either the combination treatment or dapagliflozin alone. The study employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocation. The primary purpose is treatment-focused.
Study Timeline: The study began on May 7, 2025, with the last update submitted on July 8, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status, indicating active data collection and analysis phases.
Market Implications: This study could significantly impact AstraZeneca’s stock performance and investor sentiment, as successful outcomes may enhance the company’s portfolio in the CKD treatment market. The study’s focus on the Eurasian Economic Union could also position AstraZeneca favorably against competitors in this region, potentially increasing market share.
The study is ongoing, with further details available on the ClinicalTrials portal.